Trial Profile
A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Varlitinib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
- Focus Registrational; Therapeutic Use
- Acronyms JADETREE
- Sponsors ASLAN Pharmaceuticals
- 19 Sep 2019 Results published in an ASLAN Media Release.
- 19 Sep 2019 According to an ASLAN Pharmaceuticals media release, data from this trial was presented during an oral session by Dr Weijia Fang, Associated Chief Physician, MD, Department of Medical Oncology, Zhejiang University, at the 2019 Chinese Society of Clinical Oncology (CSCO) meeting in Xiamen, China
- 27 Aug 2019 According to an ASLAN Pharmaceuticals media release, a late-breaking abstract detailing results from this trial has been accepted for oral presentation at the upcoming 2019 Chinese Society of Clinical Oncology (CSCO) in Xiamen, China on 19th September 2019.The abstract will be presented in an oral session by Dr. Weijia Fang (Associated Chief Physician, M.D., Department of Medical Oncology, Zhejiang University).